Healing · 5mg × 10 vials
KPV is the working end of alpha-MSH stripped to its smallest active form, and it shuts off the master inflammation switch (NF-kB) inside cells, with the strongest signal in gut and skin tissue where the carrier transporter is upregulated.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13), three amino acids: Lysine-Proline-Valine. Alpha-MSH is a well-characterized endogenous anti-inflammatory hormone, and the published research established that almost all of the anti-inflammatory activity of alpha-MSH lives in this final three-amino-acid tail, with none of the pigmentary or MC receptor-driven side effects of the full peptide. The proposed primary mechanism is intracellular: KPV enters the cell (likely via the PepT1 oligopeptide transporter, which is upregulated in inflamed gut tissue) and directly inhibits the NF-kB inflammatory pathway by interfering with IkB phosphorylation and p65 nuclear translocation. Downstream of that, the production of TNF-alpha, IL-1beta, IL-6, IL-8, and other pro-inflammatory cytokines drops. KPV also appears to inhibit mast cell degranulation and reduce neutrophil chemotaxis, which is why the skin inflammation models (atopic dermatitis, psoriasis, acne) respond alongside the gut models. The gut effect is amplified by the fact that PepT1 is overexpressed in inflamed colon tissue, so KPV concentrates exactly where it is needed. In plain language: KPV is the working end of alpha-MSH stripped to its smallest active form, and it shuts off the master inflammation switch (NF-kB) inside cells, with the strongest signal in gut and skin tissue where the carrier transporter is upregulated.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Bread-and-butter dose for general anti-inflammatory work, mild eczema/psoriasis, low-level autoimmune-adjacent symptoms, or as the "skin + gut" complement to a BPC-157 cycle. 5 mg vial reconstituted with 2 ml BAC = 2.5 mg/ml, 250 mcg = 0.10 ml = 10 IU on a U-100 syringe. One 5 mg vial lasts 20 days at this dose, so a KPV5 kit (5 mg x 10 vials) covers ~200 days of continuous use, well past a full cycle.
Working dose for active gut inflammation (IBD/UC/Crohn's adjunct, IBS flare), moderate psoriasis/atopic dermatitis, or autoimmune flare management. Split dosing AM + PM is preferred for gut work because of the short half-life, keeping intestinal exposure steadier across the day. 10 mg vial reconstituted with 2 ml BAC = 5 mg/ml, 500 mcg = 0.10 ml = 10 IU. One 10 mg vial lasts 20 days at 500 mcg/day.
Aggressive protocol for active IBD flares, severe psoriasis, or stacked autoimmune presentations. Combining SubQ (systemic) with oral capsule (gut-targeted, lit up via PepT1) is the community-favored maximalist approach, with the rationale that the two routes reach different tissue compartments without competing. Almost always paired with BPC-157 at this level, this is THE gut healing stack in practice.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
oral KPV reduces colitis severity in DSS mouse model via PepT1
Read study ↗PubMedDalmasso et al, PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Gastroenterology 2008mechanism paper on PepT1 transport in inflamed colon
Read study ↗PubMedBrzoska et al, Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory and protective effects, Endocrine Reviews 2008definitive review of the alpha-MSH / KPV anti-inflammatory axis
Read study ↗PubMedMastrofrancesco et al, KPV modulates inflammation in human keratinocytes, J Invest Dermatolskin/dermatology mechanism, NF-kB inhibition in keratinocytes
Read study ↗PubMedBettenworth et al, Nanoparticle-based delivery of KPV in colitistargeted delivery research, validates oral/colon route
Read study ↗PubMedLuger et al, Alpha-MSH-related peptides in immune regulationbroader immune/cytokine context
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Injection site reactions: very rare, mild redness occasionally reported, resolves within hours
"Nothing happens" reports: most common community complaint, KPV is subtle, the inflammation signal drops gradually over 1-3 weeks rather than producing a noticeable acute effect. Users expecting a BPC-157-like immediate gut quieting often underdose or quit too early
Headache: occasionally reported in the first week, usually transient
Skin flare paradox: rare reports of an initial brief worsening of psoriasis/eczema in the first few days, theory is cytokine redistribution as the inflammation settles, resolves by week 2-3
- Divergence: literature reports essentially zero adverse signal, community reports the "nothing happens" subjective experience often enough that customer expectation needs to be set up front. KPV is not a peptide that delivers a felt sensation, the read-out is the inflammation symptom (gut, skin) gradually improving over weeks
Route: SubQ (most common), oral capsule (gut-targeted, survives GI better than most peptides due to tripeptide size + PepT1 transport), topical compound (skin)
Injection site: SubQ abdomen, outer thigh, or love handle for systemic anti-inflammatory effect. Local skin injection near a chronic inflammation site (psoriasis plaque, eczema patch) is the community variation for dermatologic use, same logic as local BPC-157 for tendon work.
Storage: Refrigerated, 4-6 weeks once reconstituted. Lyophilized vials stable at room temp for shipping; refrigerate on arrival. Short half-life in solution means fresher recon is meaningfully better than month-old recon for skin/gut work.
Notes: KPV is one of the few peptides where oral capsule (10-500 mcg) is a legitimate route, not a workaround. The tripeptide is small enough and the PepT1 transporter makes oral delivery to inflamed gut tissue plausible, which is why every IBD/colitis study runs oral or rectal. For systemic skin work, SubQ wins. For gut-specific work (UC, Crohn's, IBS-flare), oral or rectal compounding is the published route. Topical cream compounding (1% in a base) is the dermatologic option for localized skin conditions.